Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 140-144 , 25 January 2010

Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNγ-transduced tumor cell immunotherapy of experimental glioma

  • Salina Gunnarsson

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, BMC B10, Lund University, SE-221 84 Lund, Sweden
    • Corresponding Author InformationCorresponding author. Postal address: BMC D14, The Rausing Laboratory, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden. Tel.: +46 46 222 14 40; fax: +46 46 222 46 06.
    web address
    • ,
  • Daniel Bexell

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, BMC B10, Lund University, SE-221 84 Lund, Sweden
    • ,
  • Andreas Svensson

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, BMC B10, Lund University, SE-221 84 Lund, Sweden
    • ,
  • Peter Siesjö

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • ,
  • Anna Darabi

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • ,
  • Johan Bengzon

      Affiliations

    • The Rausing Laboratory, BMC D14, Division of Neurosurgery, Department of Clinical Sciences, Lund University, SE-221 84 Lund, Sweden
    • Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, BMC B10, Lund University, SE-221 84 Lund, Sweden

Received 3 September 2009 ,Revised 23 October 2009 ,Accepted 23 October 2009.

References 

  1. Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, et al. Expression of murine interleukin 7 in a murine glioma cell-line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. U. S. A. 1992;89:3850–3854
  2. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Molec. Ther. 2009;17:183–190
  3. Bexell D, Gunnarsson S, Siesjo P, Bengzon J, Darabi A. CD133+ and nestin+tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int. J. Cancer. 2009;125:15–22
  4. Bexell, D., Gunnarsson, S., Tormin, A., Oliveira, A., Paul, G., Scheding, S., Bengzon. J., Comparative analysis of rat bone marrow-derived and subventricular zone-derived precursor cells as cellular vectors in glioma gene therapy. (in preparation).
  5. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol. Med. 2001;7:259–264
  6. Ehtesham M, Samoto K, Kabos P, Acosta FL, Gutierrez MA, Black KL, et al. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther. 2002;9:925–934
  7. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood. 2002;99:3892–3904
  8. Janelidze S, Bexell D, Badn W, Darabi A, Smith KE, Fritzell S, et al. Immunizations with IFNgamma secreting tumor cells can eliminate fully established and invasive rat gliomas. J. Immunother. 2009;32:593–601
  9. Kittipatarin C, Khaled AR. Interlinking interleukin-7. Cytokine. 2007;39:75–83
  10. Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin. Immunol. 2007;123:155–165
  11. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65:3307–3318
  12. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11:1155–1164
  13. Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer A, et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature. 1988;333:571–573
  14. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009;15:528–536
  15. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006;29:313–319
  16. Saleh M, Jonas NK, Wiegmans A, Stylli SS. The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. Gene Ther. 2000;7:1715–1724
  17. Salford, L., Siesjo, P., Skagerberg, G., Ask, E., Rydelius, A., Blennow, C., et al., Immunisation with autologous glioma cells transfected with IFN-γ gene significantly prolongs survival of patients with Glioblastoma Multiforme. (in preparation).
  18. Schneider T, Gerhards R, Kirches E, Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J. Neurooncol. 2001;53:39–46
  19. Siesjo P, Visse E, Lindvall M, Salford L, Sjogren HO. Immunization with mutagen-treated (tum-) cells causes rejection of nonimmunogenic rat glioma isografts. Cancer Immunol. Immunother. 1993;37:67–74
  20. Smith KE, Janelidze S, Visse E, Badn W, Salford L, Siesjo P, et al. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int. J. Cancer. 2007;120:75–80
  21. Smith KE, Fritzell S, Badn W, Eberstal S, Janelidze S, Visse E, et al. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells. Int. J. Cancer. 2009;124:630–637
  22. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol. 2004;22:4272–4281
  23. Visse E, Siesjo P, Widegren B, Sjogren HO. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7-1-transfected tumor cells. Cancer Gene Ther. 1999;6:37–44
  24. Visse E, Johansson AC, Widegren B, Sjogren HO, Siesjo P. Immunohistochemical analysis of glioma-infiltrating leucocytes after peripheral therapeutic immunization with interferon-gamma-transfected glioma cells. Cancer Immunol. Immunother. 2000;49:142–151
  25. Yamanaka R, Yajima N, Abe T, Tsuchiya N, Homma J, Narita M, et al. Dendritic cell-based glioma immunotherapy. Int. J. Oncol. 2003;23:5–15
  26. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973–4979

PII: S0165-5728(09)00432-9

doi: 10.1016/j.jneuroim.2009.10.017

Journal of Neuroimmunology
Volume 218, Issue 1 , Pages 140-144 , 25 January 2010

Article Tools

* Image Usage & Resolution